Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Camille Bedrosian Sells 12,039 Shares

Key Points

• Camille Bedrosian, an insider at Amylyx Pharmaceuticals, sold 12,039 shares at an average price of $14.58, totaling over $175,000, and now owns 182,336 shares of the company.
• Amylyx Pharmaceuticals' stock price recently dropped to $13.29, while its market capitalization stands at $1.19 billion, with a 1-year low of $2.60 and high of $15.15.
• The company reported an EPS of (0.46) for the last quarter, missing analysts' expectations and projecting an annual EPS of (2.2) for the current year.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Camille Bedrosian sold 12,039 shares of the firm's stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $14.58, for a total transaction of $175,528.62. Following the transaction, the insider directly owned 182,336 shares of the company's stock, valued at $2,658,458.88. This represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Amylyx Pharmaceuticals Price Performance

AMLX traded down $0.71 during trading on Thursday, reaching $13.29. 3,330,605 shares of the company's stock were exchanged, compared to its average volume of 1,254,741. Amylyx Pharmaceuticals, Inc. has a 1 year low of $2.60 and a 1 year high of $15.15. The stock has a market capitalization of $1.19 billion, a P/E ratio of -5.32 and a beta of -0.34. The company's fifty day simple moving average is $10.09 and its 200-day simple moving average is $6.87.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.02). Equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $45,000. BNP Paribas Financial Markets grew its stake in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after acquiring an additional 5,904 shares during the period. Legal & General Group Plc acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $47,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Amylyx Pharmaceuticals in the 1st quarter valued at $35,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AMLX shares. UBS Group raised shares of Amylyx Pharmaceuticals to a "hold" rating in a report on Tuesday, June 24th. Citigroup started coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday, June 17th. They set a "buy" rating and a $12.00 target price for the company. Bank of America lifted their target price on shares of Amylyx Pharmaceuticals from $10.00 to $14.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Wall Street Zen raised shares of Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, July 18th. Finally, Jefferies Financial Group started coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday, June 24th. They set a "hold" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $14.50.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.